Axitinib and nivolumab for advanced mucosal melanoma
Treatments studied
Part of Cancer clinical trials.
This trial studies how well two medicines—axitinib and nivolumab—work for people with advanced melanoma that starts in moist “mucosal” areas (like the mouth, nose, throat, or bowel). It may help shrink tumors and control the disease by boosting the immune system and targeting tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or unresectable mucosal melanoma from head/neck, GI tract, or genitourinary areas
- Your scans show at least one measurable tumor spot outside the brain
- You have not had prior whole-body (systemic) cancer treatment for metastatic disease (except special prior use of nivolumab + axitinib within this study in some groups)
- Your general health is good enough (ECOG performance status 0 to 2)
- Your blood tests and organ function meet minimum thresholds (counts, liver enzymes, bilirubin, and kidney filtering)
- If you can become pregnant or have a pregnant partner, you must use 2 reliable contraception methods for months after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs with standard chemotherapy (bevacizumab, albumin-bound paclitaxel, and carboplatin) for people with advanced acral or mucosal melanoma. The goal is to see if this combination can shrink tumors or slow the cancer's growth better than current treatments.
This trial tests a combination of two drugs (carilizumab and apatinib) plus radiation therapy for people with advanced mucosal melanoma that has come back or spread. The goal is to see if this treatment can help control the cancer.
This trial tests whether two medications, lenvatinib (a targeted therapy) and pembrolizumab (an immunotherapy), given before and after surgery, can help reduce the chance of mucosal melanoma coming back. If you are eligible, you would receive these drugs in addition to your standard surgery.
This trial tests whether a combination of two immunotherapy drugs (nivolumab and relatlimab) can clear tiny amounts of cancer cells that remain after surgery in people with high-risk melanoma. It aims to prevent the cancer from coming back.
This trial tests a combination of three immunotherapy drugs (ipilimumab, relatlimab, and nivolumab) given before surgery to people with melanoma that can be completely removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Hear when a new Mucosal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.